Anti-angiogenic therapy in the setting of TACE: an elusive synergy ?
Mené sur 889 patients atteints d'un carcinome hépatocellulaire non résécable (durée médiane de suivi : 17,3 mois), cet essai multicentrique international (Japon, Corée du Sud et Taiwan) évalue, du point de vue de l'amélioration de la survie globale, l'intérêt d'ajouter à une chimio-embolisation artérielle transcathéter conventionnelle l'orantinib, un inhibiteur multikinase administré par voie orale
Non-surgical treatment strategies for hepatocellular carcinoma, such as transarterial chemoembolisation (TACE), are vital for improving overall survival and quality of life. Despite being considered a standard therapy for intermediate-stage patients, categorised as Barcelona Clinic Liver Cancer (BCLC) stage B,1 TACE's palliative nature, limited efficacy, and risk of causing associated liver deterioration limits its use in daily clinical practice. Nonetheless, the known association between TACE and a spike in the intratumoural concentration of VEGF has led several investigators to evaluate the potential synergistic effects of TACE with anti-angiogenic molecularly targeted agents.
The Lancet Gastroenterology & Hepatology , commentaire, 2016